InMed Pharmaceuticals(US:INM)2020-01-15 20:28Company Overview - InMed is focused on developing cannabinoid pharmaceuticals for diseases with high unmet medical needs, researching rare cannabinoids beyond THC & CBD [11] - The company is developing a biosynthetic manufacturing approach to achieve low-cost production of biologically identical cannabinoids [11] - The company's cash equivalents and short-term investments were C$14.8 million (US$11.2 million) as of September 30, 2019 [36] INM-755 for Epidermolysis Bullosa (EB) - INM-755 is being investigated for symptomatic relief in all EB patients, potentially accelerating wound healing, reducing pain and itch, and reducing inflammation [21] - Clinical trials for INM-755 include Phase I studies in healthy volunteers and Phase I/II studies in EB patients [23] - The company initiated a Phase 1 trial (755-101-HV) [24] INM-088 for Glaucoma - INM-088 targets reducing intraocular pressure (IOP) and providing neuroprotection for retinal ganglion cells (RGCs) in glaucoma [27] - The company plans to complete formulation development and proof-of-concept animal studies in the first half of 2020 [28] Manufacturing and Intellectual Property - The company is developing a proprietary biosynthesis process for cannabinoid manufacturing, offering cost savings and enhanced purity compared to extraction from plants or chemical synthesis [13, 16] - The company has a patent portfolio including methods for treating EBS with cannabinoids (INM-755) and cannabinoid-based therapy for glaucoma (INM-088) [31] - The company has 172.3 million shares outstanding [36]